<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04464213</url>
  </required_header>
  <id_info>
    <org_study_id>HS201901</org_study_id>
    <nct_id>NCT04464213</nct_id>
  </id_info>
  <brief_title>Human Placental Mesenchymal Stem Cells Treatment on Diabetic Foot Ulcer</brief_title>
  <official_title>Phase I Clinical Trials of Human Placental Mesenchymal Stem Cells Treatment on Diabetic Foot Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designated to:&#xD;
&#xD;
        1. investigate the tolerance and safety of treatment of Human placental mesenchymal stem&#xD;
           cells gel on Human diabetic foot ulcer.&#xD;
&#xD;
        2. learn the primary effectiveness of Human placental mesenchymal stem cells gel on Human&#xD;
           diabetic food ulcer.&#xD;
&#xD;
        3. study the pharmacokinetics of Human placental mesenchymal stem cells gel on Human&#xD;
           diabetic food ulcer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adverse event</measure>
    <time_frame>0 hour - 24 hours</time_frame>
    <description>The rate of adverse event in 24 hours after single dose of Human placental mesenchymal stem cells gel on Human diabetic food ulcer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse event</measure>
    <time_frame>0 Day - 7 Days</time_frame>
    <description>The rate of adverse event in 7 days after multi-dose of Human placental mesenchymal stem cells gel on Human diabetic food ulcer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of serious adverse event</measure>
    <time_frame>0 hour - 1 hour</time_frame>
    <description>The rate of serious adverse event in 1 hour after single dose of Human placental mesenchymal stem cells gel on Human diabetic food ulcer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cure rate</measure>
    <time_frame>0 day - 34 days</time_frame>
    <description>Rate of cure rate in 20 days and 34 days after multi-dose of Human placental mesenchymal stem cells gel on Human diabetic food ulcer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Single dose experiments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-dose experiments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Single dose experiments</intervention_name>
    <description>In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time.</description>
    <arm_group_label>Single dose experiments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multi-dose experiments</intervention_name>
    <description>In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.</description>
    <arm_group_label>Multi-dose experiments</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 and Age ≤ 75&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus, glycosylated hemoglobin ≤ 9.0%&#xD;
&#xD;
          -  Diagnosed as condition of diabetic foot ulcer, Wagner grade at 1 or 2 after clinical&#xD;
             treatment&#xD;
&#xD;
          -  Full understand the informed consent form, and signed it voluntarily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feed women or plan to pregnant or fail to take an efficient&#xD;
             contraception&#xD;
&#xD;
          -  Be allergic to any component of the drug or showed allergic constitution&#xD;
&#xD;
          -  Showed a sign of systemic infection, or with complication of ethmyphitis, or&#xD;
             osteomyelitis indicated by MRI&#xD;
&#xD;
          -  Have malignancy in the ulcer pathology test, or have a history of malignant tumor&#xD;
&#xD;
          -  Unable to clean the wounds due to the formation of tract between the ulcer and other&#xD;
             condition&#xD;
&#xD;
          -  Infected with hepatitis B virus (HBV), hepatitis virus C (HCV), human immunodeficiency&#xD;
             virus (HIV), or treponema pallidum&#xD;
&#xD;
          -  Alanine transaminase (ALT) or aspartate transaminase (AST) exceeds 2.5 times of the&#xD;
             normal value, or Cr&gt;200 μmol/L&#xD;
&#xD;
          -  Have a history of apoplexy, unstable angina pectoris, myocardial infarct&#xD;
&#xD;
          -  Have a psychiatric history, drug abuse or alcohol abuse history&#xD;
&#xD;
          -  Had participated in any other clinical trials in the past 3 months&#xD;
&#xD;
          -  Any other circumstances judged by the researchers disqualify the patient to&#xD;
             participate in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zhao, Doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital, CMU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siyang Ni, Doc</last_name>
    <phone>+(86)-18911810275</phone>
    <email>grandnsy@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beiijng</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siyang Ni, Doc</last_name>
      <phone>+（86）-18911810275</phone>
      <email>grandnsy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human placental mesenchymal stem cells</keyword>
  <keyword>Gel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

